Background: Although local treatments for cervical intraepithelial neoplasia (CIN) are highly effective, it has been reported that treated women remain at increased risk of cervical and other cancers. Our aim is to explore the risk of developing or dying from cervical cancer and other human papillomavirus (HPV)-and non-HPV-related malignancies after CIN treatment and infer its magnitude compared with the general population. Materials and methods: Design: Systematic review and meta-analysis. Eligibility criteria: Studies with registry-based follow-up reporting cancer incidence or mortality after CIN treatment. Data synthesis: Summary effects were estimated using random-effects models. Outcomes: Incidence rate of cervical cancer among women treated for CIN (per 100 000 woman-years). Relative risk (RR) of cervical cancer, other HPV-related anogenital tract cancer (vagina, vulva, anus), any cancer, and mortality, for women treated for CIN versus the general population. Results: Twenty-seven studies were eligible. The incidence rate for cervical cancer after CIN treatment was 39 per 100 000 woman-years (95% confidence interval 22e69). The RR of cervical cancer was elevated compared with the general population (3.30, 2.57e4.24; P < 0.001). The RR was higher for women more than 50 years old and remained elevated for at least 20 years after treatment. The RR of vaginal (10.84, 5.58e21.10; P < 0.001), vulvar (3.34, 2.39e4.67; P < 0.001), and anal cancer (5.11, 2.73e9.55; P < 0.001) was also higher. Mortality from cervical/vaginal cancer was elevated, but our estimate was more uncertain (RR 5.04, 0.69e36.94; P ¼ 0.073). Conclusions: Women treated for CIN have a considerably higher risk to be later diagnosed with cervical and other HPVrelated cancers compared with the general population. The higher risk of cervical cancer lasts for at least 20 years after treatment and is higher for women more than 50 years of age. Prolonged follow-up beyond the last screening round may be warranted for previously treated women.
INTRODUCTION
The introduction of systematic call and recall screening programmes has resulted in a profound decrease in the incidence and mortality from cervical cancer. 1 This is because preinvasive precursors [cervical intraepithelial neoplasia (CIN)] can be detected and treated. 2 Although local cervical treatment of CIN is highly efficacious, treated women continue to represent a high-risk group, as the recurrence rate for high-grade preinvasive disease can be as high as 5%e10%. 3 Furthermore, and despite increased surveillance, these women have been reported to have a higher risk of invasive cervical cancer than the general population for several years after treatment. 4e8 The impact of different treatment methods (excisional or ablative) on the risk of future invasion remains largely unclear.
This increase in risk may be caused by persistent or recurrent human papillomavirus (HPV) infections or residual preinvasive disease that can be more difficult to detect and prevent. 9, 10 It has also been suggested that women who develop CIN constitute a subgroup of infected women who are particularly sensitive to the infection and as a result rapidly acquire reinfections after local treatment. This places them at possibly higher risk of not only cervical, but also other HPV-related neoplasms.
Estimating the relative risk (RR) of cervical cancer in treated women compared with those who were not treated is important for determining the age of the last screening and in formulating follow-up strategies that would allow risk stratification for this high-risk population. In most Western societies, screening for treated women is similar to that of the general population and this is not more intensive or different in length. The age of the last screening, at the age of 60 or 65 years in most countries, has been previously debated, 11 particularly in the context of a previous local treatment. 8, 12, 13 In the USA, previously treated women are advised to attend screening for 20 years after treatment, even if this extends beyond the age of 65 years, 13 although this is not practised in most European settings. High-quality reviews that summarise effect estimates may inform policy makers and allow more tailored screening strategies for this population. Furthermore, awareness of the risk for other HPV-related malignancies may also increase awareness and early detection for these neoplasms.
A systematic review and meta-analysis published 13 years ago reported a 56 per 100 000 woman-years incidence rate (IR) of cervical cancer after CIN treatment, which was thought to be three times greater than the expected rate in the UK. 14 This meta-analysis included predominantly small studies without centralised follow-up, did not compare to an untreated reference population, and did not explore the risk of non-cervical neoplasms. Since then, there have been several new large population-based studies with nationwide or regionwide follow-up on all cancer-related incidences and mortality. Pooled effect estimates from these studies have not been summarised and reported.
The aim of this review was to the estimate the absolute risk of developing or dying from cervical cancer, and HPVand non-HPV-related malignancies after CIN treatment, and to further explore how this compares with the risk reported in the general population.
MATERIALS AND METHODS
We registered our protocol with PROSPERO (CRD42018111659) and followed the PRISMA guidelines for reporting (supplementary Table S1 , available at Annals of Oncology online). 15 
Eligibility criteria and outcomes
We included studies reporting on the absolute incidence of cervical cancer or relative incidence and mortality of cervical, HPV-related, or non-HPV-related cancers after local treatment of CIN. Studies were eligible if they used nationwide or regionwide cancer registries as a source of follow-up data, and presented data with at least 5 years of follow-up. We excluded studies where hysterectomy was the primary treatment of CIN in the analysis for cervical cancer incidence. When a subset of the study population had hysterectomy, these women were removed if data were provided separately. If this was not possible, the study was retained if the proportion of women undergoing hysterectomy was less than 10%. For other cancers, we also included studies where the primary CIN treatment was hysterectomy. Studies assessing recurrence rates in women with microinvasive and invasive cervical cancer were excluded. Studies reporting on the outcomes of interest after treatment of both CIN and invasive disease without providing separate data were excluded. In cases of duplicate studies reporting on the same population, we retained the largest study for analysis. We preferred cohort studies to case-control, and those using a 'lag' period of at least 6 months between treatment and beginning of cancer incidence follow-up, to avoid the inclusion of cancer cases present but missed at the time of the original treatment. Data from duplicate studies were included in subgroup analyses, where applicable. There were no language or other restrictions.
For each outcome of interest (incidence and mortality of cervical, other HPV-related, non-HPV-related malignancies) we explored both absolute and relative measures compared with the reference population. We focused on the IR defined as the number of cases or deaths per woman-years. We also included RR or hazard ratio (HR) when the reference group included women without CIN, and standardised incidence ratio (SIR) or standardised mortality ratio (SMR) when the general population was used as a reference.
Literature search, data extraction and assessment of risk of bias
We searched Medline, Embase, and Central from inception to 18 August 2018 for eligible studies (search strategy in supplementary Methods, available at Annals of Oncology online). From each study, we extracted, independently and in duplicate, data on the study design, setting, demographics, CIN grades, treatment method used, length of the follow-up, data sources, and outcomes. We also extracted data on the reference population where available. We extracted data on the absolute and relative incidence and mortality for different follow-up time periods, age groups, histological CIN grades, and for each treatment technique when these were provided. Disagreements were resolved by discussion.
Our objective was to explore the absolute and relative incidence of malignancies in women previously treated for CIN versus untreated populations. We therefore used the Quality in Prognosis Studies (QUIPS) tool 16 (supplementary Methods, available at Annals of Oncology online) to explore the risk of bias at the study level independently and in duplicate using six domains: study participation, study attrition, prognostic factor measurement (i.e. treatment of CIN), outcome measurement, adjustment of outcome measurements, and statistical analysis and reporting.
Data synthesis and assessment of heterogeneity
We fitted a generalised linear mixed model using the log transformation to synthesise the raw IRs of cancer amongst Annals of Oncology treated women per 100 000 woman-years. 17, 18 We backtransformed the summary absolute IRs to the original scale to ease interpretation. The between-study variance was estimated using the maximum likelihood method. 19 Studies reporting on relative cancer incidence and mortality used RR, HR, SIR, or SMR to compare the risks between treated and untreated or the general population. Since the prevalence of CIN treatment or cervical cancer in the general population is low, we considered SIR, HR, and RR to be comparable and therefore meta-analysed them jointly. 20, 21 The pooled RRs, along with their 95% confidence interval (CI) for cancer incidence and mortality, were estimated using the random-effects model, since we anticipated clinical and methodological heterogeneity. We estimated the summary cancer incidence or mortality RR and its 95% CI using the Hartung-Knapp-Sidik-Jonkman method 22, 23 to handle meta-analyses with a small number of studies. The between-study variance was estimated using the Paule-Mandel estimator 24, 25 for the relative estimates, and its 95% CI using the Q-profile approach. 26 Full details of the analysis are included in supplementary Methods, available at Annals of Oncology online.
For all meta-analyses, we quantified the between-study heterogeneity using the I 2 statistic. In meta-analyses of relative effects, we also calculated a 95% CI for the I 2 statistic. 27e29 If there was evidence of substantial heterogeneity and more than two studies were available, the possible reasons for this were investigated through sensitivity and subgroup analyses (supplementary Methods, available at Annals of Oncology online). We calculated 95% prediction intervals (PIs) for the absolute and relative treatment effect estimates accounting for between-study heterogeneity to obtain a range in which the predicted true treatment effect in a new study is expected to lie. 30 We were not able to formally assess for publication bias and small-study effects in our meta-analyses of relative effects due to the small number of studies (<10) in each outcome. 31 The effect of publication bias in studies assessing prevalence or absolute incidence of cancer is not well established, so we did not perform any such analysis. All analyses were carried out in R V.3.4.3 32 using the metafor package 33 ; all forest plots were plotted using the meta package. 34 
RESULTS

Characteristics of studies
We retrieved 13 171 potentially eligible papers, of which 27 publications from 24 cohort studies met the inclusion criteria ( Figure 1 ). 4,5,7,8,35e57 The characteristics of the studies are reported in Tables 1 and 2 . All studies except two described retrospective cohorts; one was a nested case-control study, 38 and one reported the pooled analysis for three cohorts within The Netherlands. 45 The mean or median follow-up time varied from 5 to 27.5 years. The largest study included 150 883 women and the smallest 72. More details are found in supplementary Results, available at Annals of Oncology online.
Seven additional studies met the inclusion criteria, 46,58e63 but were excluded from the main analysis because they presented duplicate results of the same population. Some data from the duplicate studies were used in the subgroup analyses. 46 The reasons for preferential inclusion of a study over the duplicate on the same population are explained in supplementary Table S2 , available at Annals of Oncology online.
Thirteen cohorts reported on absolute 7,8,35,41e43,45e49,51e53 and 10 cohorts on relative 7,8,35,41,42,46,48,49,51e53 cervical cancer incidence after CIN treatment. The treatment methods used were reported in eight cohorts. 7,35,42,43,45e49 Four cohorts 7, 35, 48, 49, 53 excluded women treated primarily with hysterectomy (supplementary Results, available at Annals of Oncology online). Seventeen cohorts provided data on the relative incidence of other cancers than cervical cancer 5,8,36e40,44,46,47,50e52,54e57 Ten cohorts reported on relative HPV-related non-cervical female anogenital cancer incidence [six on vaginal, seven on anal, seven on vulvar, and four on cervical plus vaginal (not separately) cancer relative incidence]. 5, 8, 36, 37, 40, 44, 46, 47, 50, 52, 56 Nine cohorts reported on relative non-HPV-related cancer incidence (five on endometrial, five on ovarian, five on breast, five on lung, and five on colorectal cancer relative incidence). 39,46,50e52,54e57 One cohort 4 
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Risk of bias assessment
The risk of bias assessment of the included studies is presented in supplementary Table S3 , available at Annals of Oncology online. Only two publications scored a high risk of bias in one or more domains. 38, 47 The risk of selection bias was deemed to be moderate in five studies 4, 38, 39, 43, 46 that did not have histological confirmation of CIN for the whole cohort. The risk of attrition bias was overall deemed to be low, as all studies used centralised registries. The risk of bias on prognostic factor measurement (i.e. treatment of CIN) was moderate in fourteen cohorts, 5,8,36e38,40e42,44,51,53e57 as these may have included women with untreated CIN grade 2 (CIN2) 37, 40, 42, 53 or women treated with hysterectomy. 5,8,36e38,40e42,44,51,54e57 The lack of lag period between treatment and the start of follow-up introduced a moderate risk for outcome measurement bias in six studies. 39, 41, 43, 51, 52, 55 Lack of adjustment for age or calendar period introduced a moderate risk of bias in two studies 48, 53 and was unclear in another two. 43, 45 Statistical analysis and reporting did not lead to an increase in the risk of bias apart from two studies, due to selected grouping of treatment modalities 47 or a case-control design. 38 
Cervical cancer
The pooled absolute IR of cervical cancer after treatment of CIN per 100 000 woman-years was reported in 11 cohorts (IR 39, 95% CI 22e69; I 2 99%; 11 cohorts, 1155 cancers, 5 562 889 woman-years) ( Figure 2 ; supplementary Table S4 and supplementary Figure S1 , available at Annals of Oncology online). 7,8,35,41e43,47e49,51e53 In the subgroup analyses, the IR for older women (50 years 35,43,45e47 One cohort assessed IR after ablative treatments 46 and one after cryotherapy 7, 49 ; meta-analysis was not possible. The risk for cervical cancer after any local treatment of any grade of CIN was found to be higher in treated women rather than the reference population (RR 3.30, 2.57e4.24, I 2 83%; nine cohorts, 1145 cancers, 229 118 treated women) ( Figure 3 ; supplementary Table S5 and supplementary Figure S2 , available at Annals of Oncology online). 7,8,35,41,42,48,49,51e53 This means that the lag period varied from 0 to 12 months, depending on the month when treatment was carried out. e Number of women is not reported. Instead, only number of 'episodes' is reported. An episode was defined as the following: 'An episode started with an abnormal smear/biopsy until the f-u of this abnormal smear/biopsy was completed according to guidelines; after the f-u of the abnormal test was completed and woman returned to regular screening, each normal test was considered a separate episode. Additionally, if more than 4 years had passed since the last test, this was considered a new episode.' f Only women with three consecutive normal cytology smears were included. The interval between last abnormal smear and third consecutive normal smear was allowed to be 1.5d2 years (recommended: 2 years). If abnormal smear, the counter was reset to zero. was much uncertainty in the random-effects meta-analysis of RR after ablative treatment because of only two studies being included with non-overlapping CIs. A fixed-effect metaanalysis estimated the RR 2.69 (0.94e7.65) for ablation (supplementary Figure S2 , available at Annals of Oncology online). The summary estimates for cervical RRs were highest in the early follow-up period, but remained consistently elevated thereafter. Our estimate for RR after 20 years was more uncertain, due to the small sample size (RR 2.40, 0.83e 6.93, I 2 0%). However, the inverse variance method (randomor fixed-effect) reduced uncertainty (RR 2.40, 1.60e3.60) (supplementary Figure S2 , available at Annals of Oncology online).
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Anogenital HPV-related cancers
Eleven cohorts were included in the meta-analysis of the RRs of anogenital HPV-related cancers (Figure 4 ; supplementary Table S6 and supplementary Figure S3 , available at Annals of Oncology online). 5,36e 38,40,44,46,47,50,52,56 The RR of vaginal cancer was elevated in women treated for CIN (RR 10.84, 5.58e21.10, I 2 82%; six cohorts, 329 cancers, 518 516 treated women) and likewise 
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for vulvar cancer (RR 3.34, 2.39e4.67, I 2 64%; seven cohorts, 455 cancers, 511 315 treated women), and anal cancer (RR 5.11, 2.73e9.55, I 2 92%; seven cohorts, 534 cancers, 635 390 treated women). The RR of cervical or vaginal cancers combined were elevated compared with the general population (RR 5.71, 1.18e27.58, I 2 82%; four cohorts, 1503 cancers, 237 350 treated women). Likewise, for the risk of any anogenital HPV-related cancer (RR 3.69, 2.29e5.94; I 2 45%; seven cohorts, 1360 cancers, 548 316 treated women).
Non-HPV-related cancers
Nine cohorts reported on the RR of non-HPV-related cancers ( Figure 4 ; supplementary Table S6 and supplementary Figure S3 , available at Annals of Oncology online). 39,46,50e 52,54e57 The risk of any cancer after CIN treatment was slightly elevated compared with the general population (RR 1.14, 0.98e1.32, I 2 84%; four cohorts, 3124 cancers, 125 586 treated women). By a different statistical technique (random-effects inverse variance model) we obtained narrower CIs (any cancer: RR 1.14, 1.04e1.25) (supplementary Figure S3 , available at Annals of Oncology online). The only malignancy for which we had strong evidence that it had higher risk amongst the treated was lung cancer (RR 1.82, 1.32e2.52, I 2 86%; five cohorts, 700 cancers, 209 710 treated women).
Mortality
Three cohorts were included in the meta-analysis of the mortality from cervical and/or vaginal cancer after CIN treatment (Figure 4 ; supplementary Table S6 and supplementary Figure S3 , available at Annals of Oncology online). 4, 5, 47 We found that mortality from cervical/vaginal cancer was elevated compared with untreated women, but our estimate was uncertain (RR 5.04, 0.69e36.94, I 2 90%; three cohorts, 376 deaths, 176 782 treated women). Using the random-effects inverse variance model, we obtained narrower CIs (RR 5.04, 2.04e12.49) (supplementary Figure S3 , available at Annals of Oncology online). Meta-analysis of mortality from only cervical cancer, other cancers, or any cause was not possible because of the inadequate number of studies.
Subgroup and sensitivity analyses
The between-study heterogeneity of the absolute IR of cervical cancer was reduced when subgroup analyses were carried out according to CIN grade and length of follow-up. In the subgroup analysis after treatment of CIN3 alone, sensitivity analyses according to geography reduced heterogeneity (supplementary Table S4 , available at Annals of Oncology online).
For the RR of cervical cancer, heterogeneity was reduced in subgroup analyses according to age and method of treatment (supplementary Table S5 , available at Annals of Oncology online).
Including only European studies reduced heterogeneity for anal, ovarian, cervical/vaginal, and any female HPVrelated anogenital cancer. For vaginal and vulvar cancer, heterogeneity was still high for European countries, but choosing studies only from Northern or Western Europe reduced I 2 . For lung cancer, sensitivity analyses could not explain the high heterogeneity (supplementary Table S6 , available at Annals of Oncology online). The effect estimates did not markedly change in the sensitivity analyses, apart from cervical/vaginal and anal cancer, where including only European studies at low risk of bias and studies only from Northern Europe, respectively, reduced the point estimates.
In order to confirm that selection of SIR or RR/HR did not affect point estimates or heterogeneity, we meta-analysed studies with HR/RR and SIR separately, and found no marked differences in the point estimates or heterogeneity. In two outcomes (anal and any HPV-related female anogenital cancer) sensitivity analysis of RR/HR reduced heterogeneity, but this could be explained by inclusion of only European studies for these two sensitivity analyses.
DISCUSSION
Main findings in the context of current literature Although the cancer-preventive effect of local CIN treatment is as high as 95%e99%, 7, 48 women after treatment are thought to be at higher risk of cervical disease than the general population. Our analysis estimated the pooled absolute IR for cervical cancer to be 39/100 000 woman-years, which is consistent with the only previously published pooled analysis (56/100 000 woman-years). 14 Our pooled rate was slightly lower and likely more accurate, as we have included only studies with centralised follow-up, eliminating overestimates that may result from small single-arm studies pooled in the previous report. 14 Our findings show that the pooled cervical cancer RR amongst treated women was three times higher than the general population. This risk remains elevated for at least 20 years after the index treatment. These results were also in agreement with a previously published report. 14 The RR of other HPV-related anogenital cancers was also markedly raised in treated as opposed to untreated women. The risk of non-HPV-related malignancies was not increased when compared with the general population, with the exception of a twofold rise in lung cancer, possibly reflecting a significantly higher prevalence of smokers amongst women treated for CIN, given that smoking is a known risk factor for CIN. 64 We found that mortality was five times higher than that in the general population, although there was uncertainty around this estimate.
In recent decades, there has been a transition from more radical excision with cold knife conisation (CKC) that was routinely practiced in the 1980s to laser conisation, and to the less aggressive large loop excision of the transformation zone (LLETZ) in the 1990s that is practiced predominantly to date. 8, 65 The subsequent increased awareness that treatment, particularly excisional, increases the risk of preterm birth and other adverse reproductive outcomes in subsequent pregnancies 66e71 has led to further reduction in the radicality of treatment, with more clinicians opting for smaller excision, 72 or even ablative treatment. 66 The previously published Cochrane review exploring the comparative efficacy of excision versus ablation was grossly underpowered to show a difference for highly efficacious treatment; this would require a large, appropriatelypowered non-inferiority trial that has yet to be conducted. 73 A recent meta-analysis provided indirect evidence that LLETZ when compared with CKC, and incomplete as compared with complete margin clearance, affects treatment failure rates (7 versus 2% and 17 versus 4%, respectively). 3 The impact of less radical treatments on the future risk of invasion remains unclear. 5, 74 Although we carried out analyses for excisional and ablative techniques separately, these were not informative and were limited by the small number of studies. In one study, the point estimate for cervical cancer was higher after ablative than excisional treatment. 46 In two cohorts exploring the differences between treatment methods, cryotherapy was shown to increase cervical cancer risk threefold when compared with other local methods 48 or CKC. 49 The pooled RRs after excisional or ablative treatment were elevated compared with the reference population, although based on just a few studies and small numbers of incident cancers.
There are a number of plausible theories explaining the increase in the risk of cervical cancer after CIN treatment. A number of cases predominantly diagnosed close to the index treatment may be a result of inadequate disease excision, disease hidden in the endocervical crypts, and misdiagnosis of invasive malignancies as preinvasive. To minimise the risk of inflating the pooled cancer incidence due to misdiagnosis, all but one study used a lag-period of at least 6 months from the time of treatment to capture faults in diagnosis. Despite this, the incidence of cervical cancer was comparatively higher in the early follow-up periods, although this continued to be higher than the general population for more than two decades. Residual preinvasive disease within or outside of the endocervical crypts is harder to detect and prevent after previous treatment, as cytology and colposcopy can be more difficult to perform adequately and interpret. 41 Avoiding heavy cauterisation of the crater during treatment might decrease the risk of 'burying' residual disease inside the crypts, which subsequent cytology and colposcopy might not be able to detect.
'Lingering' disease, persistent high-risk HPV infection, and misdiagnosis could only partly explain the prolonged increase in the risk of invasive cancer after CIN treatment in some cases. The higher risk of all other HPV-related malignancies and the slightly higher risk in women over the age of 50 years suggest further possible explanations. Although cervical cancer is not considered to be a hereditary disease, there is evidence to suggest that genetic polymorphisms, 75 variations in immune defences and an innate immune system, 76 microbiome predisposition 77 and an inherent sensitivity to HPV infection and persistence in some individuals may increase their risk of HPV-related malignancies. These women are often particularly sensitive to the infection and rapidly get re-infected even if they clear this at the time of treatment.
This analysis may inform more personalised screening strategies in women previously treated for CIN and assist decision-making for clinicians and health policy makers. The interruption of cervical screening for previously treated women at an age similar to that of the general population has been long debated. 78 Advocates of prolonged screening for the subset of treated women note that the second peak in cervical cancer incidence, as well as peak incidence of other HPV-related cancers, is observed after the end of screening, 79 whereas cervical cancer mortality increases with advancing age. 80 Our findings support this notion, as the risk remained high for more than 20 years after Annals of Oncology treatment and was slightly higher for women over 50 years old. Prolonged screening after treatment for 20 years, or even for the remainder of their lifetime, may enhance prevention of cervical cancer, but may also promote early detection of asymptomatic vulvar, vaginal, and other HPVrelated neoplasms post-treatment, as these women will attend health services and have an examination of the anogenital area. Further recommendations on strategies for the prevention and early detection of non-cervical malignancies are limited by the absence of currently validated screening tools. Future research should further explore the value and cost-effectiveness of preventative interventions for other HPV-related malignancies (such as vault sample and/or colposcopic inspection in hysterectomised women for the prevention of vaginal and vulvar cancer, and anal sampling with anoscopy for anal cancer). With the introduction of the hrHPV DNA test in primary screening and HPV prophylactic vaccination, current screening programmes have undergone substantial reconfiguration making previously published evidence difficult to apply to awaited future screening structures. The expected prolongation of screening intervals may allow extension of current screening programmes beyond the age of 65 years, in line with prolonged life expectancy, particularly for treated women. These results also support further education for lifestyle, sexual, and behaviour changes that may enhance the prevention of HPV-related malignancies, and further emphasise the need for smoking cessation initiatives.
Strengths and weaknesses
This is the first systematic review and meta-analysis of observational studies with centralised follow-up assessing cancer incidence and mortality after treatment of CIN. Centralised registry data offer great advantages in minimising losses to follow-up due to population movement, and attrition bias that can arise from women facing barriers to healthcare access or without symptoms prompting them to seek medical advice, when based on the records of a single clinic. The risk of bias in included studies was, overall, considered to be low. Furthermore, we used the Knapp-Hartung-Sidik-Jonkman method for our analyses, which is known to outperform the traditional Wald type method, particularly in the context of a limited number of studies. This method usually produces more conservative estimates, reduces the risk of spurious results, and is robust to the use of different estimators for the between-study variance.
There were several limitations in our meta-analyses. In some of these analyses, there was high between-study heterogeneity, resulting in uncertainty in the estimated effects. Subgroup and sensitivity analyses according to age, CIN grade, treatment method, or length of follow-up were able to reduce heterogeneity to some extent, although many included only a small number of studies. Furthermore, we could not reliably assess for small-study effects or publication bias due to the dearth of studies. Finally, we were unable to perform subgroup analyses for the status of post-treatment test-of-cure (HPV testing and/or cytology at 6 months) due to limitations in the published data. Future studies should stratify cancer rates to HPV status after treatment.
Conclusions
Women treated for CIN have an increased incidence of not only cervical, but of all HPV-related female genital tract cancers, compared with the general population. Treated women remain at increased risk for developing invasive cervical cancer for more than 20 years. Our findings suggest that a sufficiently long follow-up, perhaps lifelong, after the end of organised screening may be warranted for this highrisk population previously treated for CIN.
